Navigation Links
Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
Date:11/19/2008

WOODCLIFF LAKE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide inhalation suspension, which is a generic form of AstraZeneca's Pulmicort Respules(R) indicated for the maintenance treatment of asthma. Par began shipping 0.25 mg/2 ml and 0.5 mg/2 ml to the trade today.

Full-year US sales for PULMICORT(R) in 2007 totalled $964 million, about 90 percent of which is accounted for by PULMICORT RESPULES(R).

Important information about budesonide inhalation suspension

Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.

Budesonide inhalation suspension is not indicated for the relief of acute bronchospasm.

Budesonide inhalation suspension is contraindicated as the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. Hypersensitivity to budesonide or any of the ingredients of this preparation contraindicates the use of budesonide inhalation suspension.

Please read full prescribing information available at www.parpharm.com/products.

About Par Pharmaceutical Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward- looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2007, in Item 1A of the Company's subsequent Quarterly Reports on Form 10-Q, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
2. Pharmaceutical Industry Needs to Speed Up Transformation to Meet Changing Market Dynamics, According to Ernst & Young Report
3. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
4. KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q
5. MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
6. Lees Pharmaceutical Kept Up the Rapid Pace of Growth; Profit Attributable to Shareholders Surged 176% in the Nine Months of 2008
7. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
8. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
9. Radiopharmaceutical Cardiolite has 15 Percent More Market Share than Myoview for September 2008
10. Irvine Pharmaceutical Services Introduces New Fill-and-Finish Subsidiary
11. KV Pharmaceutical to File Form 12b-25 on November 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy ... the preferred physical therapy provider for Derby City CrossFit, effective immediately. , In ... as quickly and effectively as possible, ProRehab’s sports physical therapists will work with ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... contracted partners to help with process innovation in drug formulation and manufacturing. ... along with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care to ... preventative care with all my patients to alleviate possible future issues. I am pleased to ... my office and my trained staff will assist you in any way possible.” , Dr. ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: